Capricor Therapeutics plans to amend its BLA for deramiocel after an FDA advisory committee voted 9–3 against finding substantial evidence of effectiveness for Duchenne muscular dystrophy cardiomyopathy. During its August 13 earnings call, the company said the amendment will add
